Document is current
Any future updates will be listed below
-
Authors
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Horiuchi, Nobuko
Sasajima, Cosmo
Matsumoto, Rumiko
Kawanishi, Masafumi https://orcid.org/0000-0003-4104-8548
Uchida, Saeko
Takeuchi, Tsutomu https://orcid.org/0000-0003-1111-8218
-
Funding
Funding for this research was provided by:
Taisho Toyama Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 1 November 2024
Accepted: 16 December 2024
First Online: 27 January 2025
Declarations
:
: Yoshiya Tanaka has received speaking fees and honoraria from AbbVie, Eisai, Chugai, Eli Lilly, Boehringer Ingelheim, GlaxoSmithKline, Taisho, AstraZeneca, Daiichi Sankyo, Gilead, Pfizer, UCB, Asahi-kasei, and Astellas and has received research grants from Boehringer Ingelheim, Taisho, and Chugai. Yoshiya Tanaka is an editorial board member of Rheumatology and Therapy. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Tsutomu Takeuchi has received speaking fees from AbbVie, Chugai, Eisai, Eli Lilly Japan, Gilead Sciences, Pfizer Japan, and Taisho and consulting fees from AbbVie, Eli Lilly Japan, Gilead Sciences, Mitsubishi-Tanabe, and Taisho. Nobuko Horiuchi, Cosmo Sasajima, Rumiko Matsumoto, Masafumi Kawanishi, and Saeko Uchida are employees of Taisho.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All studies were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. Each study was approved by the ethics committee at each research site, as described in the original papers [–]. Written informed consent was obtained from all patients.
